biogen idec inc (BIIB:NASDAQ GS)

Executive Profile*

Background*

Mr. Steven H. Holtzman, Steve, D.Phil., has been an Executive Vice President of Corporate Development at Biogen Idec Inc. since January 5, 2011. Mr. Holtzman founded Infinity Pharmaceuticals Inc. in 2006 and served as its Chief Executive Officer from September 2006 to January 1, 2010 and also its President from October 2007 to October 2008. He has substantial experience in building collaborations with major pharmaceutical companies and licensing products. He Co-Founded ... Infinity Discovery, Inc. and served as its Chief Executive Officer and Chairman from 2001 to 2006. He served as the President of Infinity Discovery from July 2001 to February 2006. He served as the Chief Business Officer of Millennium Pharmaceuticals Inc. from 1994 to 2001. He has been the Chairman of Satori Pharmaceuticals, Inc. since April 2010. Mr. Holtzman Co-Founded the Biotechnology Industry Organization (BIO) Bioethics Committee and served as its Co-Chair from 1995 to 2000. Prior to Millennium, he Founded DNX Corporation and served as its Executive Vice President and President of DNX Bio-Therapeutics Inc. from 1986 to 1994. He served as an Executive Chairman of Infinity Pharmaceuticals, Inc. since December 31, 2010. He served as the Chairman of the Board at Anadys Pharmaceuticals Inc. from July 2010 to January 4, 2011. He served as an Executive Chairman of the Board at Infinity Pharmaceuticals Inc. from September 2006 to December 31, 2010. He has been a Director of Satori Pharmaceuticals Inc. since 2009 and Satori Pharmaceuticals, Inc. since 2009. He serves as a Director of Sartori Pharmaceuticals, Inc. (US). He has been a Director and a Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He serves as a Trustee of The Hastings Center for Bioethics and the Berklee College of Music. Mr. Holtzman served as founding Executive Director of the Ohio Edison Program since 1980. He served as a Director of Archemix Corp. He served as Independent Director of Anadys Pharmaceuticals Inc. from August 2004 to January 4, 2011. He served as a Member of Supervisory Board at Amsterdam Molecular Therapeutics (AMT) Holding N.V from September 20, 2010 to January 3, 2011. He served as a Director of DNX Corporation. From 1996 to 2001, he served as a Presidential Appointee to the United States National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He was an instructor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. in the 1970s. Mr. Holtzman received a BA in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
BIIB:US	$226.85 USD	-1.14

COMPETITOR COMPENSATION